Jazz Pharmaceuticals (JAZZ) Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $732.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 23.21% year-over-year to $732.3 million in Q1 2026; TTM through Mar 2026 was $4.5 billion, a 28.99% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 40.14% from the prior year.
• Operating Expenses declined to $732.3 million in Q1 2026 per JAZZ's latest filing, from $943.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $1.7 billion in Q2 2025 and bottomed at $726.2 million in Q1 2022.
• The 5-year median for Operating Expenses is $847.3 million (2022), against an average of $927.2 million.
• Across the five-year window, Operating Expenses declined 28.01% in 2023 and surged 110.11% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $1.2 billion in 2022, then retreated by 28.01% to $889.4 million in 2023, then grew by 0.9% to $897.4 million in 2024, then climbed by 5.12% to $943.4 million in 2025, then slipped by 22.38% to $732.3 million in 2026.
• Per Business Quant, the three latest JAZZ Operating Expenses figures stand at $732.3 million (Q1 2026), $943.4 million (Q4 2025), and $1.1 billion (Q3 2025).